Thomas LaFramboise

8.8k total citations
83 papers, 3.0k citations indexed

About

Thomas LaFramboise is a scholar working on Molecular Biology, Cancer Research and Genetics. According to data from OpenAlex, Thomas LaFramboise has authored 83 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Molecular Biology, 27 papers in Cancer Research and 20 papers in Genetics. Recurrent topics in Thomas LaFramboise's work include Cancer Genomics and Diagnostics (22 papers), Acute Myeloid Leukemia Research (16 papers) and Genomic variations and chromosomal abnormalities (13 papers). Thomas LaFramboise is often cited by papers focused on Cancer Genomics and Diagnostics (22 papers), Acute Myeloid Leukemia Research (16 papers) and Genomic variations and chromosomal abnormalities (13 papers). Thomas LaFramboise collaborates with scholars based in United States, Germany and Spain. Thomas LaFramboise's co-authors include Mehmet Koyutürk, Matthew Ruffalo, Peter C. Scacheri, Cynthia F. Bartels, Matthew Meyerson, Sanford D. Markowitz, Sarah McMahon, Michael P. Schnetz, Gregory E. Crawford and Batool Akhtar‐Zaidi and has published in prestigious journals such as Science, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Thomas LaFramboise

80 papers receiving 3.0k citations

Peers

Countries citing papers authored by Thomas LaFramboise

Since Specialization

Citations

This map shows the geographic impact of Thomas LaFramboise's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas LaFramboise with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas LaFramboise more than expected).

Fields of papers citing papers by Thomas LaFramboise

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas LaFramboise. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas LaFramboise. The network helps show where Thomas LaFramboise may publish in the future.

Co-authorship network of co-authors of Thomas LaFramboise

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas LaFramboise. A scholar is included among the top collaborators of Thomas LaFramboise based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas LaFramboise. Thomas LaFramboise is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Genomics of deletion 7 and 7q in myeloid neoplasm: from pathogenic culprits to potential synthetic lethal therapeutic targets 2023 ·Leukemia ·Minako Mori, Yasuo Kubota, Arda Durmaz, Carmelo Gurnari, Charnise Goodings, Vera Ademà, Ben Ponvilawan, Waled Bahaj, Tariq Kewan, Thomas LaFramboise, Manja Meggendorfer, Claudia Haferlach, John Barnard, Marcin W. Włodarski, Valeria Visconte, Torsten Haferlach, Jaroslaw P. Maciejewski	10
2	Novel DNA Methylation Biomarker Panel for Detection of Esophageal Adenocarcinoma and High-Grade Dysplasia 2022 ·Clinical Cancer Research ·Ming Yu, Helen Moinova, Amber Willbanks, (unknown), Ting Wang, Kelly Carter, Andrew M. Kaz, Deepti Reddi, John M. Inadomi, E. Georg Luebeck, Prasad G. Iyer, Marcia Irene Canto, Jean S. Wang, Nicholas J. Shaheen, Prashanti N. Thota, Joseph Willis, Thomas LaFramboise, Amitabh Chak, Sanford D. Markowitz, William M. Grady	11
3	Circulating microbial content in myeloid malignancy patients is associated with disease subtypes and patient outcomes 2022 ·Nature Communications ·(unknown), (unknown), Stephan Hütter, Carmelo Gurnari, J. M. Sanchez, Janet Wang, Yimin Huang, (unknown), (unknown), Wanying Xu, (unknown), (unknown), Babal K. Jha, Mehmet Koyutürk, Jaroslaw P. Maciejewski, Torsten Haferlach, Thomas LaFramboise	28
4	The Ephrin B2 Receptor Tyrosine Kinase Is a Regulator of Proto-oncogene MYC and Molecular Programs Central to Barrett’s Neoplasia 2022 ·Gastroenterology ·(unknown), (unknown), (unknown), (unknown), Peronne Joseph, Salendra Singh, (unknown), (unknown), (unknown), (unknown), Adam Kresak, Dawn Dawson, Thomas LaFramboise, Joseph Willis, Amitabh Chak, Katherine S. Garman, Andrew E. Blum, Vinay Varadan, Kishore Guda	12
5	Mitochondrial DNA Content Is Linked to Cardiovascular Disease Patient Phenotypes 2021 ·Journal of the American Heart Association ·(unknown), Ying Ni, Peter Bazeley, (unknown), Janet Wang, (unknown), Stanley L. Hazen, W.H. Wilson Tang, Thomas LaFramboise	19
6	Clinical and basic implications of dynamic T cell receptor clonotyping in hematopoietic cell transplantation 2021 ·JCI Insight ·Simona Pagliuca, Carmelo Gurnari, Sanghee Hong, Ran Zhao, Sunisa Kongkiatkamon, (unknown), (unknown), Yihong Guan, Hassan Awada, Ashwin Kishtagari, Cassandra M Kerr, Thomas LaFramboise, Bhumika J. Patel, Babal K. Jha, Hetty E. Carraway, Valeria Visconte, Navneet S. Majhail, Betty K. Hamilton, Jaroslaw P. Maciejewski	13
7	Exonic variants undergoing allele-specific selection in cancers 2021 ·BMC Medical Genomics ·Qiyuan Li, Yuanyuan Zeng, Janet Wang, Hongkun Fang, Jintao Guo, Liying Yu, (unknown), Chaoqun Xu, Matthew L. Freedman, Thomas LaFramboise	1
8	Characterization of the Blood and Bone Marrow Microbiome of MDS Patients and Associations with Clinical Features 2020 ·Blood ·(unknown), (unknown), Yimin Huang, Janet Wang, Jesús María Hernández-Sánchez, Jaroslaw P. Maciejewski, Mehmet Koyutürk, Stephan Hütter, Torsten Haferlach, Thomas LaFramboise	1
9	Complexities and pitfalls in analyzing and interpreting mitochondrial DNA content in human cancer 2020 ·Journal of genetics and genomics ·(unknown), Thomas LaFramboise	1
10	Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett’s esophagus 2018 ·Science Translational Medicine ·Helen Moinova, Thomas LaFramboise, James Lutterbaugh, Apoorva K. Chandar, John A. Dumot, Ashley L. Faulx, Wendy Brock, (unknown), Kishore Guda, Jill S. Barnholtz‐Sloan, Prasad G. Iyer, Marcia Irene Canto, Jean S. Wang, Nicholas J. Shaheen, Prashanti N. Thota, Joseph Willis, Amitabh Chak, Sanford D. Markowitz	104
11	Germline SAMD9 and SAMD9L Alterations in Adult Myelodysplastic Syndromes 2017 ·Blood ·Yasunobu Nagata, Bartlomiej Przychodzen, Cassandra M. Hirsch, Hideki Makishima, (unknown), Babal K. Jha, Teodora Kuzmanovic, Tomas Radivoyevitch, Vera Ademà, Kenichi Yoshida, (unknown), Françesc Solé, Thomas LaFramboise, Rabi Hanna, Mikkael A. Sekeres, Seishi Ogawa, Marcin W. Włodarski, Jörg Cammenga, Jaroslaw P. Maciejewski	3
12	Detection and quantification of mitochondrial DNA deletions from next-generation sequence data 2017 ·BMC Bioinformatics ·Colleen M. Bosworth, (unknown), (unknown), Thomas LaFramboise	23
13	Germline compound heterozygous poly-glutamine deletion inUSF3may be involved in predisposition to heritable and sporadic epithelial thyroid carcinoma 2016 ·Human Molecular Genetics ·Ying Ni, (unknown), Benjamin Fletcher, Todd Romigh, Lamis Yehia, Jessica L. Mester, Leigha Senter, Farshad Niazi, Motoyasu Saji, Matthew D. Ringel, Thomas LaFramboise, Charis Eng	13
14	Whole-exome sequencing enhances prognostic classification of myeloid malignancies 2015 ·Journal of Biomedical Informatics ·Matthew Ruffalo, Holleh Husseinzadeh, Hideki Makishima, Bartlomiej Przychodzen, (unknown), Mehmet Koyutürk, Jaroslaw P. Maciejewski, Thomas LaFramboise	9
15	Integrative eQTL-Based Analyses Reveal the Biology of Breast Cancer Risk Loci 2013 ·Cell ·Qiyuan Li, Ji-Heui Seo, Barbara E. Stranger, Aaron McKenna, Itsik Pe’er, Thomas LaFramboise, Myles Brown, Svitlana Tyekucheva, Matthew L. Freedman	195
16	Calling amplified haplotypes in next generation tumor sequence data 2011 ·Genome Research ·Ninad Dewal, Yang Hu, Matthew L. Freedman, Thomas LaFramboise, Itsik Pe’er	8
17	Toward accurate high-throughput SNP genotyping in the presence of inherited copy number variation 2007 ·BMC Genomics ·Laura E. MacConaill, Micheala A. Aldred, Xincheng Lu, Thomas LaFramboise	9
18	Homozygous Deletions and Chromosome Amplifications in Human Lung Carcinomas Revealed by Single Nucleotide Polymorphism Array Analysis 2005 ·Cancer Research ·Xiaojun Zhao, Barbara A. Weir, Thomas LaFramboise, Ming Gang Lin, Rameen Beroukhim, Levi A. Garraway, Javad Beheshti, Jeffrey C. Lee, Katsuhiko Naoki, William G. Richards, David J. Sugarbaker, Fei Chen, Mark A. Rubin, Pasi A. Jänne, Luc Girard, John D. Minna, David C. Christiani, Cheng Li, William R. Sellers, Matthew Meyerson	242
19	A transforming MET mutation discovered in non-small cell lung cancer using microarray-based resequencing 2005 ·Cancer Letters ·Torstein Tengs, (unknown), J. Guillermo Paez, Xiao‐Jun Zhao, Thomas LaFramboise, Georgia Giannoukos, Roman K. Thomas	29
20	Statistical Analysis of Genomic Tag Data 2004 ·Statistical Applications in Genetics and Molecular Biology ·Thomas LaFramboise, D. Neil Hayes, Torstein Tengs	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact